GSK says tests show Vir antibody drug works against Omicron
GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has indicated that the drug also works against the new Omicron variant.
Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.
ALSO READ
-
High-Stakes Diplomacy in Doha: Navigating Peace amidst Middle East Tensions
-
Diplomatic Delays: Iran-U.S. Talks on Hold
-
Tech Stocks Surge as Middle East Tensions Ease
-
Strait of Hormuz Tensions: Oil and LNG Flows Continue Amid Escalating Conflicts
-
Iran and U.S. Prepare for Crucial Technical Talks in Doha
Google News